BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/6/2017 3:54:00 PM | Browse: 1431 | Download: 1754
 |
Received |
|
2016-09-03 09:36 |
 |
Peer-Review Started |
|
2016-09-03 20:06 |
 |
To Make the First Decision |
|
2016-10-20 09:20 |
 |
Return for Revision |
|
2016-10-24 15:14 |
 |
Revised |
|
2016-10-26 00:33 |
 |
Second Decision |
|
2016-11-10 14:26 |
 |
Accepted by Journal Editor-in-Chief |
|
2016-11-10 17:39 |
 |
Accepted by Executive Editor-in-Chief |
|
2016-12-02 10:37 |
 |
Articles in Press |
|
2016-12-02 10:37 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2016-12-15 05:58 |
 |
Typeset the Manuscript |
|
2017-03-01 12:39 |
 |
Publish the Manuscript Online |
|
2017-03-06 15:54 |
ISSN |
1948-5182 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Review |
Article Title |
Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
|
Manuscript Source |
Invited Manuscript |
All Author List |
Francesca Romana Ponziani, Francesca Mangiola, Cecilia Binda, Maria Assunta Zocco, Massimo Siciliano, Antonio Grieco, Gian Lodovico Rapaccini, Maurizio Pompili and Antonio Gasbarrini |
Funding Agency and Grant Number |
|
Corresponding Author |
Cecilia Binda, MD, Internal Medicine, Gastroenterology and Hepatology, Catholic University Sacred Heart of Rome, Agostino Gemelli Hospital, Largo Agostino Gemelli 8, 00168 Rome, Italy. cecilia.binda@gmail.com |
Key Words |
Direct acting antivirals; Hepatitis C; Liver transplantation; Liver fibrosis; Cirrhosis; Hepatocellular carcinoma |
Core Tip |
The approval of new direct acting antivirals with high rates of virological clearance and excellent tolerability has dramatically improved hepatitis C virus (HCV) infection curability, especially for patients with advanced liver disease and for liver transplant recipients. The aim of this review is to draw the possible future scenery in HCV-related liver disease, focusing our attention on the impact of second generation direct acting antivirals on liver fibrosis, hepatocellular carcinoma and liver transplantation. |
Publish Date |
2017-03-06 15:54 |
Citation |
Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367 |
URL |
http://www.wjgnet.com/1948-5182/full/v9/i7/352.htm |
DOI |
http://dx.doi.org/10.4254/wjh.v9.i7.352 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345